New mutants of apolipoprotein E associated with atherosclerotic diseases but not to type III hyperlipoproteinemia.
Open accessAbstract
We analyzed the heterogeneity of apo E in very low density lipoprotein from 58 hyperlipidemic subjects with or without atherosclerosis, 69 patients with ischemic heart disease, and 100 apparently healthy individuals. Apo E gene frequencies in the group of healthy individuals were comparable with those in German and American populations. The distribution of six common apo E phenotypes in the groups of hyperlipidemia and ischemic heart disease was similar to that in the healthy group. In addition to the three major isoforms of apolipoprotein E (apo E-4, E-3, and E-2) and the new one (apo E-5) which was recently found in this laboratory, we have discovered an additional series of components, which showed themselves as at least three bands on an isoelectric focusing gel in the region of E-VII through E-V, in four patients with hyperlipidemia and atherosclerosis. The new series of apo E components, named apo E-Suita, was identical with the ordinary apo E in its interaction with heparin-Sepharose gel and with anti-apo E antibody. The most basic component of apo E-Suita (E-VII) was the unsialylated form and other components (E-VI and E-V), the sialylated forms. Family studies revealed that apo E-Suita was determined by inheritance of a new apo E allele located at the same locus as the hitherto known apo E components. Apo E-5 and apo E-Suita isoproteins had isoelectric points more basic than apo E-3, the parent type, by two and four units of charge, respectively. While the apo E-Suita isoprotein had the same molecular weight as ordinary major apo E isoproteins, the molecular weight of the apo E-5 isoprotein was approximately 1,500-2,000 lower than the other apo E isoproteins by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The incidence of abnormal apo E components, including apo E-5 and apo E-Suita, was high among patients with hyperlipidemia and ischemic heart disease (7:127), while we could not find such components among 100 healthy individuals. Moreover, five of seven patients with the abnormal apo E had overt atherosclerotic disease. The findings suggest that these kinds of apolipoprotein mutation are closely related to the development of atherosclerosis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
rs121918392 (p.E21K) was defined as the APOE ε5 allele.
“rs121918392 (p.E21K) was defined as the APOE ε5 allele29,32–34”
From Association of rare <i>APOE</i> missense variants with Alzheimer's disease in the Japanese population (2025) · cites this paper as [29]
The Introduction identifies apo E-5, and the discussion says it is controlled by an additional APOE allele. The paper does not identify that allele as rs121918392 or p.E21K; it says peptide-sequence analysis was still underway and tentatively suggests a deletion instead. (LLM, conf=0.88)
Experimental — accuracy not yet measuredrs140808909 (p.E262K) and rs190853081 (p.E263K) have been previously identified in Japanese patients with dyslipidemia and atherosclerosis and are defined as the APOE ε7 allele.
“Both variants have been previously identified in Japanese patients with dyslipidemia and atherosclerosis and is defined as the APOE ε7 allele.29–31”
From Association of rare <i>APOE</i> missense variants with Alzheimer's disease in the Japanese population (2025) · cites this paper as [29]
The Introduction and Results describe apo E mutants found in patients with hyperlipidemia and atherosclerotic disease; the discussion suggests these mutants may be limited to the Japanese population. But the paper does not identify rs140808909 or rs190853081, establish the E262K or E263K substitutions, or define either as the APOE ε7 allele. It calls the new allele apo E-Suita; E-VII denotes a protein band, not an allele name. (LLM, conf=0.88)
Experimental — accuracy not yet measuredrs121918392 (p.E21K) was also associated with dyslipidemia and atherosclerosis.
“rs121918392 (p.E21K) was also associated with dyslipidemia and atherosclerosis.29,32–34”
From Association of rare <i>APOE</i> missense variants with Alzheimer's disease in the Japanese population (2025) · cites this paper as [29]
The Results and Discussion (page unavailable) associate apo E-5 and apo E-Suita with hyperlipidemia and atherosclerotic disease. But the paper does not identify either mutant as rs121918392 (p.E21K); the Discussion says peptide sequence analysis was still underway. It therefore supports the disease association for the mutants studied, not its attribution to that specific variant. (LLM, conf=0.88)
Experimental — accuracy not yet measuredThe ε7 allele has been linked to dyslipidemia and atherosclerosis.
“Notably, the ε7 allele has been linked to dyslipidemia and atherosclerosis,29–31 yet few studies have examined its binding to LDLR and heparin. 38”
From Association of rare <i>APOE</i> missense variants with Alzheimer's disease in the Japanese population (2025) · cites this paper as [29]
The Abstract and Results describe apo E-Suita in patients with hyperlipidemia and atherosclerosis, supporting the reported link. But the paper calls the inherited allele εSuita; E-VII is the name of an electrophoretic component, not an allele the paper identifies as ε7. It therefore does not establish the claim for an ε7 allele specifically. (LLM, conf=0.83)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Human apolipoprotein E. The complete amino acid sequence
Rall, S. C., Weisgraber, K. H., & Mahley, R. W. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34702-1 · Cited by 741 · see citing works
Zannis, V. I., & Breslow, J. L. (1981) · Biochemistry · doi:10.1021/bi00507a059 · Cited by 563 · see citing works
Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes
Zannis, V. I., Breslow, J. L., Utermann, G., Mahley, R. W., Weisgraber, K. H., Havel, R. J., Goldstein, J. L., Brown, M. S., Schonfeld, G., Hazzard, W. R., et al. (1982) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38094-9 · Cited by 436 · see citing works
Rall, S. C., Weisgraber, K. H., Innerarity, T. L., & Mahley, R. W. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.15.4696 · Cited by 345 · see citing works
The receptor-binding domain of human apolipoprotein E. Binding of apolipoprotein E fragments.
Innerarity, T. L., Friedlander, E. J., Rall, S. C., Weisgraber, K. H., & Mahley, R. W. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44180-9 · Cited by 276 · see citing works
Fainaru, M., Mahley, R. W., Hamilton, R. L., & Innerarity, T. L. (1982) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38102-5 · Cited by 156 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Apolipoprotein E polymorphism and atherosclerosis.
Davignon, J., Gregg, R. E., & Sing, C. F. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.1.1 · Cited by 1,981 · see citing works
Apolipoprotein E: Structure-Function Relationships
Weisgraber, K. H. (1994) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60642-7 · Cited by 830 · see citing works
APOE gene variants in primary dyslipidemia
Khalil, Y. A., Rabès, J.-P., Boileau, C., & Varret, M. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.05.007 · Cited by 170 · see citing works
Wardell, M. R., Brennan, S. O., Janus, E. D., Fraser, R., & Carrell, R. W. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113096 · Cited by 159 · see citing works
Apolipoprotein genetic variation in the assessment of atherosclerosis susceptibility
Hegele, R. A., Breslow, J. L., & Cloninger, C. R. (1987) · Genetic Epidemiology · doi:10.1002/gepi.1370040302 · Cited by 60 · see citing works
Characterization of a new apolipoprotein E5 variant detected in two French-Canadian subjects
Mailly, F., Xu, C., Xhignesse, M., Lussier-Cacan, S., Talmud, P., Davignon, J., Humphries, S., & Nestruck, A. (1991) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42048-6 · Cited by 36 · see citing works
Miyashita, A., Obinata, A., Hara, N., Mitsumori, R., Kaneda, D., Hashizume, Y., Sano, T., Takao, M., Gabdulkhaev, R., Tada, M., et al. (2025) · Journal of Alzheimer’s Disease · doi:10.1177/13872877251340710 · Cited by 5 · see citing works
Hypertriglyceridemia and pancreatitis in a patient with apolipoprotein E7 (p.[E244K; E245K])/E4
Arai, M., Nishimura, A., Mori, Y., Ebara, T., & Okubo, M. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.06.001 · Cited by 2 · see citing works
- Authors
- Yamamura, T., Yamamoto, A., Sumiyoshi, T., Hiramori, K., Nishioeda, Y., & Nambu, S.
- Affiliations
- National Cerebral and Cardiovascular Center (JP)
- Venue
- Journal of Clinical Investigation
- Published
- 1984-10-01
- Volume
- 74
- Issue
- 4
- Pages
- 1229-1237
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC425289
- OpenAlex
- W2058222155
- Cited by
- 91
- References
- 6
- Citations by year
- 2026: 1 · 2025: 1 · 2022: 2 · 2021: 1 · 2019: 1 · 2016: 2 · 2015: 1 · 2014: 2 · 2013: 2
- FWCI
- 16.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (58480151)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, atherosclerosis, hyperlipidemia, ischemic heart disease, VLDL, sialylation, apolipoprotein E isoforms, genetic susceptibility to atherosclerosis, type III hyperlipoproteinemia
- MeSH terms
- Antigen-Antibody Reactions, Apolipoproteins E, Arteriosclerosis, Cysteamine, Female, Gene Frequency, Humans, Hyperlipoproteinemia Type III, Lipoproteins, VLDL, Male, Mutation, Neuraminidase, Phenotype, Precipitin Tests
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review